As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11,…
Congressional trades · 1 on record
Disclosures from 2022-12-12 to 2022-12-12
The newest disclosure we hold for this stock is 2022-12-12.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
Not in our coverage. KalVista Pharmaceuticals Inc isn't currently held by any of the 50 hedge funds we track. The price chart and company profile below come from public Yahoo Finance data.
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
▲
A member of Congress bought
▼
A member sold
Return: High: Low:
Markers sit on the transaction date the member disclosed, snapped to the
nearest close on the chart. They are not the date the public found out — that
came later, and
the gap is its own page.
Every marker is listed by name in the table above.
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell KalVista Pharmaceuticals Inc or any security.